Protease nexin-1 inhibitor for the treatment of haemorrhagic disease

The thrombogram of FVIII-KO mice displays a prolonged time to peak and a reduced peak thrombin. The addition of the neutralizing anti-protease nexin-1 (PN-1) antibody enhances thrombin generation in PRP from haemophilia mice. The thrombogram of patient with haemophilia displays prolonged lag time and time to peak and a reduced peak thrombin and a reduced endogenous thrombin potential. As observed with the addition of recombinant FVIII, the neutralizing anti-PN-1 antibody enhances thrombin generation in PRP from patients with haemophilia A. Anti-PN-1 antibody improves thrombin generation in mild and moderate haemophilia patients but not in severe haemophilia patients. These findings establish a requirement for PN-1 inhibition as a specific anticoagulant in platelets and demonstrated that blocking PN-1 have a role in haemorrhagic disease treatment.

Keywords : Protease nexin-1, Haemophilia
Patent Application number : EP15305544.7
Patent Application date : 2015-04-15
Multidisciplinary field : -
Technology/Engineering : -
Technological Platform : -
Rare disease : Yes
Second indication : -
Inventors : Marie-christine BOUTON
Christophe OLIVIER
Cécile DENIS
Publications : -

Related offers

The 10 Last viewed

You haven't seen any form yet.